Ignite Creation Date:
2024-05-06 @ 7:54 AM
Last Modification Date:
2024-10-26 @ 11:53 AM
Study NCT ID:
NCT02624570
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2020-07-15
First Post:
2015-12-03
Brief Title:
Midostaurin Access Program for Newly Diagnosed FLT3 ITD or TKD Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Organization Data
Organization:
Novartis
Class:
INDUSTRY
Study ID:
CPKC412AUS56X
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Novartis Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None